KineMed, Inc. and CHDI Foundation Collaborate to Develop New Biomarkers of Disease Progression and to Evaluate Potential Therapeutics for Huntington's Disease

Published: May 15, 2012

EMERYVILLE, Calif. & NEW YORK--(BUSINESS WIRE)--KineMed, Inc. ( and CHDI Foundation, Inc. announced today a collaboration to use KineMed’s isotopic labeling and dynamic proteomics platform to investigate the turnover rates of huntingtin protein, a mutant form of which plays a central role in the pathogenesis of Huntington’s disease (HD).

Back to news